Skip to main
FLGT
FLGT logo

Fulgent Genetics (FLGT) Stock Forecast & Price Target

Fulgent Genetics (FLGT) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Fulgent Genetics Inc. showcases a strong financial outlook attributed to its unique reliance on proprietary gene probes, which enhances both cost efficiency and operational flexibility compared to competitors that utilize third-party kits. The company's significant revenue generation stems primarily from its laboratory services, which include advanced technical capabilities and professional interpretation, positioning it well within the genetic testing market. Additionally, Fulgent's therapeutic development efforts demonstrate its commitment to innovation in oncology, further solidifying its potential for long-term growth in the evolving healthcare landscape.

Bears say

Fulgent Genetics is faced with significant operational risks as its efforts to scale the oncology business may lead to a deterioration in service quality due to potential unforeseen challenges during nationwide rollout. Additionally, the company's core markets are highly competitive, with the possibility that rival firms may enhance their offerings and customer service, negatively impacting Fulgent's operating results. Furthermore, regulatory uncertainties pose a considerable risk, as changes in government regulations can adversely affect the company’s business operations and financial performance.

Fulgent Genetics (FLGT) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fulgent Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fulgent Genetics (FLGT) Forecast

Analysts have given Fulgent Genetics (FLGT) a Buy based on their latest research and market trends.

According to 3 analysts, Fulgent Genetics (FLGT) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fulgent Genetics (FLGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.